Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in COVID-19 Respiratory Failure (iNSPIRE)
NCT04375397Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in coronavirus disease 2019 (COVID-19), sponsored by AbbVie Inc.. Started Jun 2020; status: completed.
02
Drugs
ibrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04375397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375397.